Actively Recruiting
Long COVID Immune Profiling
Led by Vanderbilt University Medical Center · Updated on 2025-12-15
150
Participants Needed
1
Research Sites
166 weeks
Total Duration
On this page
Sponsors
V
Vanderbilt University Medical Center
Lead Sponsor
A
American Heart Association
Collaborating Sponsor
AI-Summary
What this Trial Is About
Parasympathetic nervous system (PNS) is part of the body's autonomic nervous system(PNS) protects body against inflammation. Study shows that reduced PNS function activity is associated with persistent inflammation. Preliminary data from the studies shows, that post-COVID-19 POTS patients have reduced parasympathetic (PNS) function. Given that the PNS protects against inflammation, this clinical trial aims to prove that post-COVID-19 POTS is caused by reduced PNS activity, which in turn, contributes to persistent inflammation, orthostatic intolerance, and OI symptoms. The study will evaluate immune cell activation in post-COVID-19 POTS and patients with history of COVID-19 infection without sequelae and correlate this with the degree of decreased PNS activity.
CONDITIONS
Official Title
Long COVID Immune Profiling
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Subjects aged 18 years or older, any gender
- History of confirmed COVID-19 infection by symptoms, antigen test, or PCR
- Diagnosis of POTS defined by orthostatic tachycardia (>30 bpm) and chronic pre-syncopal symptoms lasting more than 3 months
- For post-COVID-19 POTS, symptoms started within 2 months after COVID infection and persist until study enrollment
You will not qualify if you...
- History of myocardial infarction, angina, heart failure, stroke, transient ischemic attack, or invasive cardiovascular procedures
- Inability to comply with study protocol, including uncooperative attitude or inability to attend follow-up visits
- Chronic use of steroids, anti-IL6 (omalizumab), anti-TNF-alpha, or other immunosuppressants
- Chronic use of NSAIDs, or NSAID use within one week prior to blood sampling
- Treatment with plasmapheresis, intravenous immunoglobulin (IVIG), or other immune modulators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Cyndya Shibao
Nashville, Tennessee, United States, 37027
Actively Recruiting
Research Team
M
Marwa Mohamed, Phd
CONTACT
C
Cyndya Shibao, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here